BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17404814)

  • 1. Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety.
    Denora N; Laquintana V; Lopedota A; Serra M; Dazzi L; Biggio G; Pal D; Mitra AK; Latrofa A; Trapani G; Liso G
    Pharm Res; 2007 Jul; 24(7):1309-24. PubMed ID: 17404814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel codrugs with GABAergic activity for dopamine delivery in the brain.
    Denora N; Cassano T; Laquintana V; Lopalco A; Trapani A; Cimmino CS; Laconca L; Giuffrida A; Trapani G
    Int J Pharm; 2012 Nov; 437(1-2):221-31. PubMed ID: 22940209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies.
    Bonina F; Puglia C; Rimoli MG; Melisi D; Boatto G; Nieddu M; Calignano A; La Rana G; De Caprariis P
    J Drug Target; 2003 Jan; 11(1):25-36. PubMed ID: 12852438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
    Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
    Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.
    Di Stefano A; Sozio P; Iannitelli A; Marianecci C; Santucci E; Carafa M
    J Drug Target; 2006 Nov; 14(9):652-61. PubMed ID: 17090401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
    Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
    J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
    Peura L; Malmioja K; Huttunen K; Leppänen J; Hämäläinen M; Forsberg MM; Gynther M; Rautio J; Laine K
    Pharm Res; 2013 Oct; 30(10):2523-37. PubMed ID: 24137801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Cyclodextrin dimer complexes of dopamine and levodopa derivatives to assess drug delivery to the central nervous system: ADME and molecular docking studies.
    Shityakov S; Broscheit J; Förster C
    Int J Nanomedicine; 2012; 7():3211-9. PubMed ID: 22811606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimeric L-dopa derivatives as potential prodrugs.
    Di Stefano A; Mosciatti B; Cingolani GM; Giorgioni G; Ricciutelli M; Cacciatore I; Sozio P; Claudi F
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1085-8. PubMed ID: 11327596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
    Parada A; Soares-da-Silva P
    Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.
    Jain R; Majumdar S; Nashed Y; Pal D; Mitra AK
    Mol Pharm; 2004; 1(4):290-9. PubMed ID: 15981588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption.
    Fix JA; Alexander J; Cortese M; Engle K; Leppert P; Repta AJ
    Pharm Res; 1989 Jun; 6(6):501-5. PubMed ID: 2762226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
    Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
    PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
    Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
    Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
    Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC.
    Cannazza G; Di Stefano A; Mosciatti B; Braghiroli D; Baraldi M; Pinnen F; Sozio P; Benatti C; Parenti C
    J Pharm Biomed Anal; 2005 Jan; 36(5):1079-84. PubMed ID: 15620535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
    Huang L; Deng M; He Y; Lu S; Ma R; Fang Y
    Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):634-43. PubMed ID: 26991136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
    Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 1998 Jul; 353(1):33-42. PubMed ID: 9721037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
    Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gas chromatography/mass spectrometric identification of dopaminergic metabolites in striata of rats treated with L-DOPA.
    Loutelier-Bourhis C; Legros H; Bonnet JJ; Costentin J; Lange CM
    Rapid Commun Mass Spectrom; 2004; 18(5):571-6. PubMed ID: 14978802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.